Histologic Features of Melanocytic Nevi Secondary to Melanoma Treatment With Immune Checkpoint Inhibitors.
1/5 보강
Programmed death-1 (PD-1) inhibitors are anticancer drugs that function as immune checkpoint blockers, targeting PD-1 proteins on the surface of cells to restore immune system activity against tumors.
APA
Sohail N, Sohail A, et al. (2026). Histologic Features of Melanocytic Nevi Secondary to Melanoma Treatment With Immune Checkpoint Inhibitors.. Cureus, 18(3), e105392. https://doi.org/10.7759/cureus.105392
MLA
Sohail N, et al.. "Histologic Features of Melanocytic Nevi Secondary to Melanoma Treatment With Immune Checkpoint Inhibitors.." Cureus, vol. 18, no. 3, 2026, pp. e105392.
PMID
42005225 ↗
Abstract 한글 요약
Programmed death-1 (PD-1) inhibitors are anticancer drugs that function as immune checkpoint blockers, targeting PD-1 proteins on the surface of cells to restore immune system activity against tumors. While cutaneous adverse events associated with immune checkpoint inhibitor therapy are well documented, this case highlights the reactive histopathologic changes that can occur in benign nevi during treatment. Here, we present the case of a 51-year-old Hispanic female with a history of melanoma on the chest who was seen in clinic for routine follow-up. Three suspicious pigmented lesions located on the right upper back, abdomen, and left shoulder were biopsied for further analysis. Histopathologic examination indicated an intradermal melanocytic nevus with irritation and inflammation, an inflamed, mildly dysplastic compound melanocytic nevus, and a compound melanocytic nevus with marked inflammation and no atypia. Additional clinical history revealed that the patient was receiving treatment for advanced melanoma with immune checkpoint inhibitors. Increased awareness of these features in melanocytic lesions associated with PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors may help with accurate diagnosis.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Novel roles of SETD2 in tumor metabolism and immunotherapy: a systematic review and meta-analysis.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Successful Treatment of Paranasal Sinus Metastasis From Renal Cell Carcinoma With Immune Checkpoint Inhibitors and Radiotherapy: A Case Report.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.